| Psychiatry Grand Rounds | | | « back to January calendar | Scott F. Coffey, Ph.D. | | | | | Dr. Scott Coffey is Associate Professor and Director of the Division of Psychology in the Department of Psychiatry and Human Behavior at the University of Mississippi Medical Center (UMMC). Dr. Coffey received his B.S. from Arizona State University and his Ph.D. in Clinical Psychology from the University of Mississippi. He completed his clinical internship at the Medical University of South Carolina (MUSC) and remained at MUSC as a National Institute on Drug Abuse Postdoctoral Research Fellow working with Drs. Kathleen Brady and Michael Saladin. Upon completion of his fellowship, Dr. Coffey moved to the University at Buffalo as an Assistant Professor and, in 2004, moved to UMMC to take his current position. Dr. Coffey’s research interests include treatment outcome research and laboratory-based research on substance abuse disorders, posttraumatic stress disorder, and the co-occurrence of these two conditions. In addition, Dr. Coffey has interests in elucidating underlying psychological processes, such as impulsivity and negative emotion, which may serve to maintain or initiate some psychiatric conditions, such as borderline personality disorder. His research has been funded by the National Institute on Alcohol Abuse and Alcoholism and the National Institute of Mental Health. Dr. Coffey reviews grant submissions for the National Institutes of Health and is on the Editorial Board for the Journal of Traumatic Stress. In 2004, Dr. Coffey was honored with an Excellence in Research Award (Medallion Society) from UMMC and, in 2002, was named Teacher of the Year at the University at Buffalo, Department of Psychiatry. | | | | | | | | At the completion of this session, the participant should be able to: | | | 1) Describe psychiatric conditions that commonly co-occur with borderline personality disorder. 2) Describe current empirically-supported treatments for BPD. 3) Describe how laboratory paradigms may inform the conceptualization of BPD and may inform future treatment development for BPD.
| |
| | | | | | | | | | | | | | | | | | | | |  |
|